	US 11,911,348 B2
	Therapeutic agent for cancer
Yutaka Kawakami, Shinjuku-ku (JP); Tomonori Yaguchi, Shinjuku (JP); Taeko Hayakawa, Shinjuku-ku (JP); and Atsushi Imaizumi, Hino (JP)
Assigned to THERAVALUES CORPORATION, Tokyo (JP)
Filed by THERAVALUES CORPORATION, Tokyo (JP)
Filed on Oct. 9, 2020, as Appl. No. 17/066,744.
Application 17/066,744 is a division of application No. 15/539,920, granted, now 10,849,862, previously published as PCT/JP2015/086133, filed on Dec. 24, 2015.
Claims priority of application No. 2014-264359 (JP), filed on Dec. 26, 2014.
Prior Publication US 2021/0023025 A1, Jan. 28, 2021
Int. Cl. A61K 31/12 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)

CPC A61K 31/12 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01)]

4 Claims

1. A method for treating colon cancer in a subject having cancer, comprising

administering simultaneously or separately at least one selected from the group consisting of curcumin and a derivative thereof, and at least one anti-PD-1 antibody comprising RMP1-14 CDR1, RMP1-14 CDR2 and RMP1-14 CDR3 of heavy chain and RMP1-14 CDR1, RMP1-14 CDR2 and RMP1-14 CDR3 of the light chain and the framework sequences to inhibit immunosuppressive signal by PD-1,

wherein the derivative thereof is selected from the group consisting of desmethoxycurcumin, bisdesmethoxycurcumin and tetrahydrocurcumin.